

16 September 2020

## Eye Co Appoints Experienced Director to its Fiduciary Board.

I am pleased to advise that **Alison Coutts** has accepted our invitation to join Eye Co's fiduciary board as a Non-Executive Director effective immediately.

Alison Coutts is currently the Executive Chairman of the ASX listed bio-separations business, Memphasys Ltd. She holds a Chemical Engineering degree and a Graduate Diploma in Biotechnology from the University of Melbourne and an MBA with distinction from the Melbourne Business School.

Ms Coutts brings extensive and important experience and networks across several industry sectors and disciplines to Eye Co. This includes **investment banking** at eG Capital, technology **commercialisation** with Memphasys Ltd as well as **international engineering project management, strategy consulting** with Boston Consulting Group, and **executive search** with Egon Zehnder International. She was formerly Chair of CSIRO's Health Sector Advisory Council and was a co-founder and director of eG Capital, which was a preeminent financial advisory firm in the Australian Life Sciences sector.

Eye Co is in the business of identifying and completing early stage development of technologies associated with the treatment of retinal diseases. The Company's lead compound, **Fludrocortisone Acetate**, is currently undergoing a Phase Ib safety study in humans in the treatment of **dry Age-Related Macular Degeneration** for which there are currently no available treatment options. The company's strategy is to out-license its technologies to commercialisation partners with the resources and capability to bring these technologies to patients globally.

Alison brings important skills and networks to Eye Co and we look forward to her contribution at this important stage of the Company's evolution.

Yours sincerely



Mark Grey FAICD, FCPA.  
Chairman